2019
DOI: 10.1007/s10072-019-03764-z
|View full text |Cite
|
Sign up to set email alerts
|

Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
16
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 22 publications
(16 citation statements)
references
References 79 publications
0
16
0
Order By: Relevance
“…DMD and, often, BMD are lethal conditions. Effective treatments are limited for DMD patients, and research for genetic-based therapies is ongoing [7]. As a consequence, the analysis The incidence of DMD and BMD is approximately 1 in 3500 and 1 in 20,000-30,000 live male births, respectively [6].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…DMD and, often, BMD are lethal conditions. Effective treatments are limited for DMD patients, and research for genetic-based therapies is ongoing [7]. As a consequence, the analysis The incidence of DMD and BMD is approximately 1 in 3500 and 1 in 20,000-30,000 live male births, respectively [6].…”
Section: Introductionmentioning
confidence: 99%
“…DMD and, often, BMD are lethal conditions. Effective treatments are limited for DMD patients, and research for genetic-based therapies is ongoing [7]. As a consequence, the analysis of the DMD gene is of utmost importance for the identification of the underlying molecular defect, because it can confirm the clinical diagnosis, reveal patients' genotype, address patients to the most opportune therapeutic options, and allow the identification of carrier females and the application of prenatal tests [8][9][10].…”
Section: Introductionmentioning
confidence: 99%
“…Neurologic Sciences, as done in the past years, selected the most cited articles published in the past year and granted free access to them one month (Table 1). Table 1 Values obtained through the SIMPER analysis based in the diet of the Crenicichla species from streams, Upper Jacuí and Ibicuí subbasins, Southern Brazil • Kocaturk, O., Besli, F., Gungoren, F. et al [1] The relationship among neutrophil to lymphocyte ratio, stroke territory, and 3-month mortality in patients with acute ischemic stroke • Vita, G., Vita, G.L., Musumeci, O. et al [2] Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle • Park, S.B., Kwon, K., Lee, J. et al [3] Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions • Hadjigeorgiou, G.M., Kountra, P., Koutsis, G. et al [4] Replication study of GWAS risk loci in Greek multiple sclerosis patients • Kaur, R., Mehan, S. & Singh, S. [5] Understanding multifactorial architecture of Parkinson's disease: pathophysiology to management • Defazio, G., Albanese, A., Pellicciari, R. et al [6] Expert recommendations for diagnosing cervical, oromandibular, and limb dystonia • Sansone, V.A., Albamonte, E., Salmin, F. et al [7] Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care • Buture, A., Ahmed, F., Dikomitis, L. et al .…”
Section: Brain Awarenessmentioning
confidence: 99%
“…The therapeutic scenario of spinal muscular atrophy (SMA) has been recently subverted by introduction of nusinersen [ 4 ]. Despite the high cost and different refund policies of health insurances in different countries, its availability is increasing worldwide.…”
Section: Introductionmentioning
confidence: 99%